GO:0086004 regulation of cardiac muscle cell contraction: Physiological Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0086004 describes any process that modulates the frequency, rate or extent of cardiac muscle cell contraction, encompassing ion channel regulation, calcium handling, mechanotransduction, and gene expression changes [1,4,8].
• Cardiac muscle cell contraction is driven by calcium-induced calcium release and sarcomeric actomyosin cycling, and its dysregulation underlies heart failure and arrhythmias [1,4].
• Key regulators include calcium channels (CACNA1C, RYR2), sarcomeric proteins (MYH7, TNNT2), and signaling molecules such as RBPMS that control alternative splicing [4,6].
• Intracellular calcium leak through ryanodine receptors is a unifying mechanism in heart failure and atrial fibrillation, making it a therapeutic target.
• Mechanotransduction and shear stress modulate cardiac ion channels and calcium handling, linking mechanical environment to contractile regulation [7,8].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of genes regulating cardiac contraction and disease modeling [2,5].
Description
Regulation of cardiac muscle cell contraction (GO:0086004) is a fundamental biological process that controls the strength, frequency, and duration of heart muscle cell shortening. This process ensures that the heart pumps blood efficiently and adapts to changing physiological demands. At the cellular level, contraction is initiated by calcium influx through voltage-gated calcium channels, which triggers calcium release from the sarcoplasmic reticulum via ryanodine receptors (RYR2), leading to actin-myosin cross-bridge cycling [1,4]. The regulation of this process involves multiple layers of control, including ion channel modulation, calcium handling, mechanotransduction, and gene expression changes [4,6,8]. Understanding GO:0086004 is critical for researchers studying cardiac physiology and disease. Dysregulation of cardiac contractility is a hallmark of heart failure, atrial fibrillation, and cardiomyopathies [2,4]. For example, hypocontractility-induced fibroblast expansion can exacerbate dilated cardiomyopathy, and preventing this expansion alleviates the disease in model systems. Moreover, intracellular calcium leak through RYR2 is a unifying mechanism in heart failure and atrial fibrillation, highlighting the importance of precise regulation. This article provides a comprehensive overview of the molecular players, regulatory mechanisms, and experimental approaches used to study GO:0086004. It integrates authoritative QuickGO annotations with real PubMed literature to support researchers in designing CRISPR-based experiments and interpreting contractile phenotypes.
regulation of cardiac muscle cell contraction At A Glance
| GO ID | GO:0086004 |
|---|---|
| GO term | regulation of cardiac muscle cell contraction |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulates the frequency, rate, or extent of cardiac muscle cell contraction |
| Related processes | Calcium signaling, ion transport, mechanotransduction, sarcomere organization |
| Key regulators | CACNA1C, RYR2, MYH7, TNNT2, RBPMS, and others |
| Disease relevance | Heart failure, atrial fibrillation, dilated cardiomyopathy, arrhythmias |
What Is GO:0086004?
According to the Gene Ontology, GO:0086004 (regulation of cardiac muscle cell contraction) is defined as any process that modulates the frequency, rate or extent of cardiac muscle cell contraction. This term encompasses both positive and negative regulation, including signaling pathways, ion channel activity, calcium handling, and mechanical feedback that ultimately influence the contractile state of cardiomyocytes.
Why Is regulation of cardiac muscle cell contraction Important in Cell Biology?
GO:0086004 is essential for normal cardiac function and its dysregulation is a central feature of many cardiovascular diseases. The heart must continuously adjust its contractile output to meet systemic demands, and this regulation occurs at multiple levels: from rapid modulation of ion channels and calcium handling to long-term changes in gene expression and sarcomeric composition [1,4,6]. Defects in these regulatory mechanisms can lead to arrhythmias, heart failure, and sudden cardiac death. Therefore, understanding the molecular basis of contractile regulation is crucial for developing targeted therapies and for interpreting genetic variants associated with cardiomyopathies [2,4].
• Heart failure is often characterized by impaired contractility and calcium handling, making GO:0086004 a therapeutic target.
• Atrial fibrillation is linked to intracellular calcium leak through RYR2, a key regulatory node.
• Dilated cardiomyopathy can be exacerbated by hypocontractility-induced fibroblast expansion, highlighting the role of contractile regulation in disease progression.
• Mechanotransduction and shear stress regulate cardiac ion channels and calcium signaling, integrating mechanical cues into contractile control [7,8].
• Alternative splicing regulators such as RBPMS modulate cardiomyocyte contraction and cardiac function, revealing post-transcriptional control.
• Zebrafish heart regeneration studies provide insights into how contractile regulation influences regenerative capacity.
• Direct reprogramming of fibroblasts into cardiomyocytes requires the establishment of contractile regulation networks.
• Genetic variants in sarcomeric and calcium-handling genes are associated with inherited cardiomyopathies and arrhythmias [1,4].
• CRISPR-based models enable precise dissection of gene function in contractile regulation [2,5].
• Understanding GO:0086004 aids in the development of gene therapies and pharmacological interventions for heart disease.
What Happens During regulation of cardiac muscle cell contraction?
Calcium-Induced Calcium Release and Excitation-Contraction Coupling
In simple terms: When a heart cell gets excited, calcium enters and triggers a bigger release of calcium inside the cell, which makes the cell contract.
Cardiac muscle cell contraction is initiated by membrane depolarization, which opens voltage-gated L-type calcium channels (CACNA1C), allowing calcium influx. This calcium binds to ryanodine receptors (RYR2) on the sarcoplasmic reticulum, triggering a massive release of stored calcium into the cytosol [1,4]. The rise in cytosolic calcium enables calcium binding to troponin C, which moves tropomyosin and allows actin-myosin cross-bridge cycling, resulting in sarcomere shortening and cell contraction. Regulation of this process occurs at multiple steps, including channel gating, calcium buffering, and reuptake by SERCA2a. Dysregulation of calcium handling, such as leaky RYR2, is a common mechanism in heart failure and atrial fibrillation.
Ion Channel Modulation and Membrane Potential
In simple terms: The electrical signals that control heart cell contraction are shaped by various ion channels that let sodium, potassium, and calcium move across the cell membrane.
The frequency and rate of cardiac muscle cell contraction are tightly regulated by the coordinated activity of ion channels that determine the action potential duration and shape. Sodium channels (e.g., SCN5A) initiate depolarization, while potassium channels (e.g., KCNQ1, KCNH2) mediate repolarization. Calcium channels (CACNA1C) provide the trigger for calcium release. Modulation of these channels by signaling pathways, such as beta-adrenergic stimulation, can increase contractility (positive inotropy) and heart rate (positive chronotropy). Shear stress and mechanotransduction also regulate ion channel activity, linking mechanical forces to electrical and contractile responses.
Mechanotransduction and Mechanical Feedback
In simple terms: Heart cells can sense mechanical forces like stretch and shear stress, and they respond by adjusting their contraction.
Cardiomyocytes are constantly exposed to mechanical forces, including stretch and shear stress from blood flow. These forces are sensed by mechanosensitive complexes at the cell membrane, cytoskeleton, and nucleus, leading to changes in ion channel activity, calcium handling, and gene expression [7,8]. For example, shear stress can modulate cardiac calcium channels and other ion channels, thereby influencing contractility. Nucleus mechanosensing involves proteins such as lamins and emerin, which transmit mechanical signals to the nucleus and regulate gene expression programs that affect contractile function. This feedback loop allows the heart to adapt to hemodynamic loads.
Transcriptional and Post-Transcriptional Regulation
In simple terms: The amounts and types of proteins that control contraction are regulated by gene expression and RNA processing.
Long-term regulation of cardiac muscle cell contraction involves changes in gene expression and alternative splicing. For instance, the RNA-binding protein RBPMS regulates alternative splicing of genes involved in cardiomyocyte contraction, and its loss leads to impaired cardiac function. Transcription factors such as MEF2 and GATA4 control the expression of sarcomeric and calcium-handling genes. Additionally, microRNAs and RNA-binding proteins fine-tune the contractile machinery. Direct reprogramming of fibroblasts into cardiomyocytes by defined factors (e.g., Gata4, Mef2c, Tbx5) demonstrates the importance of transcriptional networks in establishing contractile regulation.
Sarcomeric Function and Cross-Bridge Cycling
In simple terms: The actual contraction happens when actin and myosin filaments slide past each other, and this process is regulated by calcium and accessory proteins.
The sarcomere is the basic contractile unit of cardiac muscle, composed of actin (thin filaments) and myosin (thick filaments) along with regulatory proteins troponin and tropomyosin. Calcium binding to troponin C relieves inhibition of actin-myosin interaction, allowing myosin heads to bind actin and undergo the power stroke, which shortens the sarcomere. The rate and extent of cross-bridge cycling are modulated by phosphorylation of myosin-binding protein C (MYBPC3) and troponin I, as well as by mechanical load. Mutations in sarcomeric genes such as MYH7 and TNNT2 can alter contractile regulation and cause cardiomyopathy.
Key Genes Involved in GO:0086004 regulation of cardiac muscle cell contraction
The following genes and proteins are key players in the regulation of cardiac muscle cell contraction, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CACNA1C | Voltage-gated L-type calcium channel; mediates calcium influx triggering calcium release | Target for calcium channel blockers; mutations linked to Timothy syndrome and arrhythmias [1,4] |
| RYR2 | Ryanodine receptor 2; releases calcium from sarcoplasmic reticulum | Central to calcium-induced calcium release; leak causes heart failure and atrial fibrillation |
| MYH7 | Beta-myosin heavy chain; sarcomeric motor protein | Mutations cause hypertrophic and dilated cardiomyopathy |
| TNNT2 | Cardiac troponin T; regulates actin-myosin interaction | Mutations associated with hypertrophic cardiomyopathy and heart failure |
| RBPMS | RNA-binding protein; regulates alternative splicing of contractile genes | Knockout leads to impaired cardiac contraction and function |
| SCN5A | Voltage-gated sodium channel; initiates action potential | Mutations cause Brugada syndrome and arrhythmias |
| KCNQ1 | Potassium channel; mediates repolarization | Mutations cause long QT syndrome |
| KCNH2 | Potassium channel; mediates repolarization | Mutations cause long QT syndrome |
| ATP2A2 | SERCA2a; calcium pump reuptake into sarcoplasmic reticulum | Defects contribute to heart failure; target for gene therapy |
| MYBPC3 | Myosin-binding protein C; modulates cross-bridge cycling | Mutations cause hypertrophic cardiomyopathy |
| TTN | Titin; giant sarcomeric protein; provides elasticity | Mutations associated with dilated cardiomyopathy |
| ACTN2 | Alpha-actinin-2; cross-links actin filaments | Mutations linked to cardiomyopathy |
| GATA4 | Transcription factor; regulates cardiac gene expression | Essential for cardiac development and contractile gene expression |
| MEF2C | Transcription factor; regulates sarcomeric and calcium-handling genes | Key for cardiomyocyte differentiation and reprogramming |
| TBX5 | Transcription factor; cardiac development and conduction | Mutations cause Holt-Oram syndrome |
| LMNA | Lamin A/C; nuclear mechanosensing | Mutations cause dilated cardiomyopathy and muscular dystrophy |
| EMD | Emerin; nuclear envelope protein; mechanosensing | Mutations cause Emery-Dreifuss muscular dystrophy with cardiac involvement |
| NPPA | Atrial natriuretic peptide; regulates blood pressure and cardiac load | Biomarker of heart failure; regulated by contractile stress |
How Is regulation of cardiac muscle cell contraction Regulated?
The regulation of cardiac muscle cell contraction is itself subject to multiple regulatory layers. Beta-adrenergic signaling via protein kinase A (PKA) phosphorylates calcium channels, RYR2, and sarcomeric proteins to enhance contractility. Calcium/calmodulin-dependent kinase II (CaMKII) modulates calcium handling and is implicated in arrhythmias. Mechanical stretch activates integrins and stretch-activated channels, leading to changes in gene expression and contractility [7,8]. Additionally, RNA-binding proteins such as RBPMS regulate alternative splicing of contractile genes, providing post-transcriptional control. These regulatory mechanisms ensure that cardiac contractility is finely tuned to physiological demands.
regulation of cardiac muscle cell contraction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RYR2 | Heart failure, atrial fibrillation (calcium leak) | Knock-in mouse with RYR2 mutation; CRISPR point mutation in hiPSCs |
| MYH7 | Hypertrophic/dilated cardiomyopathy | Knockout or knock-in in hiPSCs; mouse models |
| RBPMS | Impaired cardiac contraction and function | Knockout mouse; CRISPR KO in cardiomyocytes |
| LMNA | Dilated cardiomyopathy, muscular dystrophy | Knock-in mouse; patient-derived iPSCs |
| TNNT2 | Hypertrophic cardiomyopathy | CRISPR knock-in of mutations in hiPSCs |
Heart Failure and Calcium Leak
Heart failure is characterized by impaired contractility and often involves dysregulated calcium handling. Intracellular calcium leak through ryanodine receptors (RYR2) is a unifying mechanism in heart failure and atrial fibrillation, contributing to arrhythmias and contractile dysfunction. This leak can be triggered by phosphorylation of RYR2 by PKA or CaMKII, and targeting this leak is a therapeutic strategy. Additionally, hypocontractility-induced fibroblast expansion can exacerbate dilated cardiomyopathy, and preventing this expansion alleviates the disease in model systems.
Cardiomyopathies and Sarcomeric Mutations
Mutations in sarcomeric genes such as MYH7, TNNT2, and MYBPC3 can alter contractile regulation and lead to hypertrophic or dilated cardiomyopathy. These mutations often affect cross-bridge cycling, calcium sensitivity, or sarcomere assembly. Understanding how these mutations impact GO:0086004 is essential for developing targeted therapies and for genetic counseling.
Arrhythmias and Ion Channel Dysfunction
Arrhythmias such as atrial fibrillation and long QT syndrome are linked to dysfunction of ion channels that regulate cardiac action potentials and contraction [1,4]. For example, mutations in SCN5A, KCNQ1, or KCNH2 can cause long QT syndrome, while calcium leak through RYR2 contributes to atrial fibrillation. These conditions highlight the importance of precise regulation of ion channels in GO:0086004.
Mechanotransduction and Nuclear Envelope Cardiomyopathies
Defects in nuclear mechanosensing proteins such as lamin A/C (LMNA) and emerin (EMD) cause dilated cardiomyopathy and muscular dystrophy. These proteins transmit mechanical signals to the nucleus and regulate gene expression, affecting contractile function. Studying these mechanisms provides insight into how mechanical forces regulate cardiac contraction in health and disease.
From regulation of cardiac muscle cell contraction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene impair cardiac contractility? | CRISPR knockout in hiPSC-derived cardiomyocytes or mouse [2,6] |
| Does a specific point mutation alter calcium handling? | CRISPR point mutation knock-in in hiPSCs |
| Does a disease-associated variant affect contractile regulation? | Knock-in of the variant in hiPSCs or mouse |
| Where is a protein localized during contraction? | Tagged knock-in (e.g., GFP) in cardiomyocytes |
| Does overexpression of a gene enhance contractility? | Overexpression via lentivirus or CRISPR activation in cardiomyocytes |
| Can reprogramming factors establish contractile regulation? | Direct reprogramming of fibroblasts with Gata4, Mef2c, Tbx5 |
How to Study the regulation of cardiac muscle cell contraction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Calcium imaging | Intracellular calcium transients | Assess calcium handling in cardiomyocytes |
| Contractility assays | Cell shortening, force generation | Evaluate contractile function [2,6] |
| Patch-clamp | Ion channel currents, action potentials | Study ion channel regulation [1,8] |
| RNA-seq | Gene expression, alternative splicing | Identify transcriptomic changes |
| Proteomics | Protein abundance, modifications | Quantify sarcomeric and signaling proteins |
| Phosphoproteomics | Phosphorylation events | Map signaling pathways regulating contraction |
| CRISPR screening | Gene function at scale | Identify novel regulators of contractility |
| Traction force microscopy | Mechanical forces exerted by cells | Measure contractile force |
Calcium Imaging and Contractility Assays
Calcium imaging using fluorescent dyes (e.g., Fluo-4) or genetically encoded calcium indicators (GCaMP) allows real-time measurement of calcium transients in cardiomyocytes. Contractility can be assessed by video edge detection, traction force microscopy, or atomic force microscopy. These methods are essential for evaluating the functional impact of genetic perturbations on GO:0086004 [4,6].
Electrophysiology
Patch-clamp electrophysiology measures ion channel currents and action potentials in cardiomyocytes. This technique is crucial for understanding how ion channel regulation contributes to contractile regulation and for assessing the effects of mutations or drugs [1,8].
Transcriptomics and Splicing Analysis
RNA sequencing (RNA-seq) and alternative splicing analysis (e.g., via rMATS) can identify changes in gene expression and splicing that affect contractile regulation. For example, RBPMS knockout alters splicing of contractile genes, which can be detected by RNA-seq. Single-cell RNA-seq can reveal heterogeneity in cardiomyocyte populations.
Proteomics and Phosphoproteomics
Mass spectrometry-based proteomics can quantify sarcomeric and calcium-handling proteins, while phosphoproteomics identifies signaling events that regulate contraction. These methods provide a systems-level view of the molecular changes underlying GO:0086004 [1,4].
How CRISPR Can Be Used to Study GO:0086004 regulation of cardiac muscle cell contraction
Knockout
CRISPR knockout (KO) is used to completely abolish the expression of a candidate gene to determine its role in cardiac muscle cell contraction. For example, KO of RBPMS in cardiomyocytes led to impaired contraction and cardiac dysfunction. KO models can be generated in hiPSCs or animal models, and contractile phenotypes can be assessed using calcium imaging and contractility assays.
Point Mutation
CRISPR point mutation knock-in introduces specific disease-associated variants to study their impact on contractile regulation. For instance, point mutations in RYR2 that cause calcium leak can be modeled in hiPSCs to investigate arrhythmia mechanisms. This approach allows precise dissection of variant effects on calcium handling and contractility.
Knock-in
CRISPR knock-in can be used to insert reporter tags (e.g., GFP) or to humanize a gene in animal models. Tagged knock-in of sarcomeric proteins enables live-cell imaging of their localization and dynamics during contraction. Knock-in of human disease variants into mouse models can recapitulate cardiomyopathy phenotypes.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression is used to increase the expression of a gene of interest to test whether it enhances contractility. For example, overexpression of transcription factors such as GATA4, MEF2C, and TBX5 can reprogram fibroblasts into cardiomyocytes, establishing contractile regulation. Overexpression studies help identify sufficiency of a gene in regulating contraction.
How EDITGENE Supports regulation of cardiac muscle cell contraction Research
Researchers studying regulation of cardiac muscle cell contraction-related genes often need to determine whether a candidate gene is causally involved in contractile regulation or is merely a biomarker. EDITGENE provides a comprehensive suite of CRISPR services to enable precise genetic perturbations in cardiomyocytes and animal models, accelerating the discovery of therapeutic targets.
Contact EDITGENE today to design your custom CRISPR model for regulation of cardiac muscle cell contraction research.
Frequently Asked Questions About regulation of cardiac muscle cell contraction
What is GO:0086004?
GO:0086004 is the Gene Ontology term for regulation of cardiac muscle cell contraction, defined as any process that modulates the frequency, rate or extent of cardiac muscle cell contraction.
What genes are involved in regulation of cardiac muscle cell contraction?
Key genes include CACNA1C, RYR2, MYH7, TNNT2, RBPMS, SCN5A, KCNQ1, KCNH2, ATP2A2, MYBPC3, TTN, and transcription factors like GATA4, MEF2C, and TBX5 [1,4,5,6].
How is cardiac muscle contraction regulated?
It is regulated by calcium-induced calcium release, ion channel activity, mechanotransduction, and transcriptional/post-transcriptional mechanisms [1,4,6,7,8].
What diseases are associated with dysregulation of cardiac muscle cell contraction?
Heart failure, atrial fibrillation, dilated cardiomyopathy, hypertrophic cardiomyopathy, and long QT syndrome are associated with dysregulation of this process [1,2,4].
What is the role of calcium in cardiac muscle cell contraction?
Calcium influx triggers calcium release from the sarcoplasmic reticulum, which activates actin-myosin cross-bridge cycling and contraction [1,4].
How can CRISPR be used to study regulation of cardiac muscle cell contraction?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise genetic perturbations to test causality of genes in contractile regulation [2,5,6].
What is the role of RYR2 in heart failure?
RYR2 mediates calcium release; leaky RYR2 causes intracellular calcium leak, a unifying mechanism in heart failure and atrial fibrillation.
What is mechanotransduction in cardiomyocytes?
Mechanotransduction is the process by which cardiomyocytes sense mechanical forces and convert them into biochemical signals that regulate contraction and gene expression [7,8].
How does RBPMS regulate cardiac contraction?
RBPMS regulates alternative splicing of genes involved in cardiomyocyte contraction; its loss leads to impaired cardiac function.
What models are used to study regulation of cardiac muscle cell contraction?
hiPSC-derived cardiomyocytes, mouse models, zebrafish, and CRISPR-engineered cell lines are commonly used [2,3,5].
Conclusion
Regulation of cardiac muscle cell contraction (GO:0086004) is a complex, multi-layered process essential for heart function. Its dysregulation contributes to major cardiovascular diseases, including heart failure and arrhythmias. Advances in CRISPR-based models and functional assays are enabling researchers to dissect the causal roles of specific genes and variants. EDITGENE provides end-to-end solutions to accelerate this research, from custom knockout and knock-in models to high-throughput screening and bioinformatics.
References
- 1. Sweeney HL et al.. 2018. Muscle Contraction.. Cold Spring Harb Perspect Biol 10(2) PMID: 29419405
- 2. Bretherton RC et al.. 2025. Preventing hypocontractility-induced fibroblast expansion alleviates dilated cardiomyopathy.. Science 390(6773):eadv9157 PMID: 40934290
- 3. Poss KD et al.. 2002. Heart regeneration in zebrafish.. Science 298(5601):2188-90 PMID: 12481136
- 4. Dridi H et al.. 2020. Intracellular calcium leak in heart failure and atrial fibrillation: a unifying mechanism and therapeutic target.. Nat Rev Cardiol 17(11):732-747 PMID: 32555383
- 5. Ieda M et al.. 2010. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors.. Cell 142(3):375-86 PMID: 20691899
- 6. Gan P et al.. 2024. RBPMS regulates cardiomyocyte contraction and cardiac function through RNA alternative splicing.. Cardiovasc Res 120(1):56-68 PMID: 37890031
- 7. Coscarella IL et al.. 2023. Nucleus Mechanosensing in Cardiomyocytes.. Int J Mol Sci 24(17) PMID: 37686151
- 8. Kim JC et al.. 2017. Regulation of cardiac Ca(2+) and ion channels by shear mechanotransduction.. Arch Pharm Res 40(7):783-795 PMID: 28702845
